Mid-Term Clinical Outcomes of Intraarticular Injection of Platelet Rich Plasma and Adipose-Derived MesenchymalStem Cells for the Treatment of Intra articular Pathology of the Knee, Hip and Shoulder
Introduction:Intraarticular injections of platelet rich plasma (PRP) and adipose-derived mesenchymalstem cells (AD-MSCs) have individually shown potential benefit in the treatment of intraarticular pathology of the knee, hip and shoulder. However, outcomes data is sparse in regards to PRP and AD-MSCs injected in the same setting. The purpose of this study is to assess the midterm clinical outcomes and safety profile of intraarticular injection of PRP and AD-MSCs into arthritic hips, knees and shoulders. Methods:After IRB approval, a retrospective chart review identified 50 patients who had received intraarticular injection of PRP and AD-MSCs into their hip, knee or shoulder for intraarticular pathology. Clinical outcomes including the need for further injections, progression to surgery and any adverse effects were collected. Patient reported outcomes scores and patient satisfaction were collected at average 2-year follow-up for 39/50 patients (78%). Results: Clinical outcomes were favorable at 2-year follow-up. Approximately 70% of people were satisfied with the results of their treatment overall. Only 4% of patients progressed to repeat PRP and AD-MSC injection into the joint of interest while 21% of patients progressed to surgery. There were no significant adverse events encountered during the 2-year period. Median improvement in clinical outcome scoreswas above the minimally clinically important difference. Conclusion: Intraarticular injections of PRP and AD-MSCs into hips, knees and shoulders are safe and have a low rate of progression to further surgery or repeat injection at 2-year follow-up. Improvement in clinical outcome scores and high patient satisfaction were demonstrated at 2-year follow-up.
